

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2789216

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BRUCE SELIGMANN	10/15/2012
KRISHNA MADDULA	10/01/2012
MATT ROUNSEVILLE	10/10/2012
IHAB BOTROS	10/10/2012
CHRIS COX	10/25/2012
RECEIVING PARTY DATA	
Name:	HTG MOLECULAR DIAGNOSTICS, INC.
Street Address:	3430 E. GLOBAL LOOP
City:	TUCSON
State/Country:	ARIZONA
Postal Code:	85706
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14347855
CORRESPONDENCE DATA	
Fax Number:	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	503-595-5300
Email:	susan.graf@klarquist.com
Correspondent Name:	SUSAN W. GRAF, KLARQUIST SPARKMAN, LLP
Address Line 1:	121 SW SALMON STREET
Address Line 2:	SUITE 1600
Address Line 4:	PORTLAND, OREGON 97204
ATTORNEY DOCKET NUMBER:	8736-87721-06
NAME OF SUBMITTER:	SUSAN W. GRAF, PH.D.
SIGNATURE:	/Susan W. Graf/
DATE SIGNED:	03/27/2014
Total Attachments: 3	
source=Assignment#page1.tif	

source=Assignment#page2.tif

source=Assignment#page3.tif

ASSIGNMENT

We, Bruce Seligmann, of Tucson, Arizona, Krishna Maddula of Tucson, Arizona, Matt Rounseville of Tucson, Arizona, Ihab Botros of Tucson, Arizona, and Chris Cox of Tucson, Arizona, have invented one or more inventions (collectively, the "Invention") as described in the following patent application(s):

U.S. Provisional Patent Application No. 61/540,387, filed on September 28, 2011, entitled "METHODS OF SIMULTANEOUSLY DETECTING MRNA AND MIRNA," and

PCT Patent Application No. PCT/US2012/057368, filed on September 26, 2012, entitled "METHODS OF CO-DETECTING MRNA AND SMALL NON-CODING RNA,"

which applications are collectively referred to herein as "the patent applications."

The Invention was made as a result of our activities at or on behalf of HTG Molecular Diagnostics, Inc. or as a result of our utilization of information, facilities or other resources of HTG Molecular Diagnostics, Inc. The conditions under which the Invention was made are such as to entitle HTG Molecular Diagnostics, Inc. to each of our entire respective right, title, and interest in the Invention and any corresponding patent applications and/or patents in the United States and its territories and dependencies, and all other countries and jurisdictions of the world.

In consideration of our obligations and other valuable consideration, we each have sold, assigned and transferred or hereby sell, assign, and transfer to HTG Molecular Diagnostics, Inc., its successors and assigns (collectively, "Assignee"), each of our respective full and exclusive right, title, and interest in the Invention, the patent applications, and any corresponding patent rights throughout the United States and its territories and dependencies, and all other countries and jurisdictions of the world. The conveyance of patent rights includes, without limitation, full and exclusive right, title, and interest in all patents claiming all or part of the Invention that may be granted in the United States and/or any other countries and jurisdictions of the world, and any divisional, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof; and the right to claim priority from any one or more of the patent applications as provided for by United States law, the Patent Cooperation Treaty, the European Patent Convention, the Paris Convention, or other applicable law.

We each authorize and request the issuance of any patents claiming all or part of the Invention and/or claiming the benefit of a filing date of any one or more of the patent applications to the Assignee to be held as fully and entirely as the same would have been held by us had this assignment not been made.

We each warrant that there are no outstanding assignments, grants, liens, encumbrances, or agreements either written, oral, or implied that will impair, diminish, limit, or abridge the interest herein conveyed.

We each also agree upon reasonable request to communicate with the Assignee, its representatives or agents, any facts known to us respecting all or part of the Invention, and testify in any legal proceedings, sign all lawful papers, execute all divisional, continuing, reexamination and/or


reissue applications, make all rightful oaths, provide all requested documents, and do everything reasonably possible to aid the Assignee, its representatives or agents, to obtain and enforce proper patent protection for all or part of the Invention in the United States or any other country of the world. These provisions are binding upon each of our heirs, legal representatives, administrators and assigns.

This Assignment may be executed in one or more counterparts, each of which when executed and delivered, by facsimile or other electronic transmission, by mail delivery, or by other legal form of delivery, will be an original and all of which will constitute but one and the same Assignment.

IN WITNESS WHEREOF, this Assignment is executed as of the date(s) indicated below.

WITNESS (Seligmann):



Bruce Seligmann



Print Name: DEB GORDON

Date: 10/15/12

Date: 15-OCT-2012

WITNESS (Maddula):



Krishna Maddula



Print Name: DEB GORDON

Date: 01-OCT-2012

Date: 01-OCT-2012

WITNESS (Rounseville):


Matt Rounseville



Print Name: DEB GORDON

Date: 10-Oct-2012

Date: 10-OCT-2012


WITNESS (Botros):


Ihab Botros


Print Name: DEB GORDON

Date: 10/10/12

Date: 10-OCT-2012


Chris Cox

Date: 10/25/12

WITNESS (Cox):

Lorraine Stewart

Print Name: Lorraine Stewart

Date: 10/25/12